Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous anti-gp100:154-162 TCR gene-engineered tumor infiltrating lymphocytes
- Development stage
- Discontinued
- Lead developer
- National Cancer Institute
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a personalized cell therapy where tumor infiltrating lymphocytes (TILs) or peripheral blood lymphocytes (PBLs) are isolated from melanoma patients and genetically engineered to express a T-cell receptor (TCR) that specifically recognizes the gp100:154-162 peptide presented by HLA-A*0201. The gp100 protein is a melanocyte lineage-specific antigen highly expressed in melanoma cells. Upon reinfusion into patients following lymphodepleting conditioning, these engineered cells can recognize and target gp100-expressing melanoma cells, potentially leading to tumor regression.
- Other names
- autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes
02
Targets
gp100:154-162 (Melanocyte protein PMEL (gp100) peptide-HLA-A*0201 complex)
Beyond the preview
Go deeper on autologous anti-gp100:154-162 TCR gene-engineered tumor infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous anti-gp100:154-162 TCR gene-engineered tumor infiltrating lymphocytes.